Manic episodes in two patients treated with interferon alpha

Strite, Daniel; Valentine, Alan D.; Meyers, Christina A.

doi:10.1176/jnp.9.2.273

Cited by 57 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common side effects, which occur early in treatment and tend to dissipate as treatment continues, include flu-like symptoms such as fever, tachycardia, headache, malaise, arthralgia, and myalgia [22]. Neuropsychiatric side effects in some cases appear later in treatment and include fatigue, affective changes (depression, anxiety, irritability, manic symptoms, and even suicidal behavior), cognitive changes (decreased concentration, confusion, and delirium), and, rarely, psychosis [23–25]. …”

Section: Introductionmentioning

confidence: 99%

Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C

Ramsey

Engler²,

Stein³

et al. 2011

J Addict Res Ther

View full text Add to dashboard Cite

To examine the efficacy of a cognitive-behavioral intervention (CBT) to prevent depression among methadone maintenance patients undergoing antiviral treatment for hepatitis C (HCV), 29 patients beginning HCV treatment were randomized to CBT or standard care (SC). Study participants did not meet criteria for major depressive disorder at the time of study recruitment. CBT did not result in less depression-related antiviral treatment failure, better adherence to antiviral treatment, or better HCV RNA outcomes. There were no significant treatment group differences on depressive symptoms over time. The CBT group did display a greater and more consistent decline in both BDI-II and HAM-D scores over time (d=.85 on the BDI-II; d=.72 on the HAM-D).

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C

Ramsey

Engler²,

Stein³

et al. 2011

J Addict Res Ther

View full text Add to dashboard Cite

show abstract

Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes

Greenberg¹,

Jonasch²,

Gadd³

et al. 2000

Cancer

View full text Add to dashboard Cite

BACKGROUND The use of a high dose regimen of interferon‐alpha‐2b (IFN) has recently been demonstrated to benefit patients with resected high risk melanoma. The incidence of melanoma is rising rapidly, and the use of this regimen is becoming increasingly common. IFN has been associated with numerous psychiatric side effects. METHODS The authors describe four melanoma patients treated with adjuvant IFN who developed a manic‐depressive syndrome or mood instability with therapy, and they review the literature on mania and the mixed affective syndromes associated with IFN. RESULTS The authors suggest that IFN may induce a mixed affective instability, and that patients risk developing hypomania or mania as IFN doses fluctuate or as IFN‐induced depression is treated with antidepressants alone. Mania is particularly associated with dose reductions or pauses in IFN treatment. The risk of mood fluctuation continues after treatment with IFN stops, and patients should be monitored for 6 months following completion of therapy. Gabapentin appeared effective as monotherapy for acute mania, as an antianxiety agent, as a hypnotic, and as a mood stabilizer in these individual cases. CONCLUSIONS Mania and mood instability can occur in patients being treated with IFN therapy for melanoma. In this study, gabapentin was an effective mood‐stabilizing agent for these patients. Cancer 2000;89:356–62. © 2000 American Cancer Society.

show abstract